ATGC Inc. (ATGC) is “A Translational Genomics Company”.

The company is dedicated to the development of novel transgenic rabbits as discovery platforms and bioreactors to produce therapeutic biologics such as monoclonal antibodies.

Our mission is to discover the best-in-class therapeutics through the novel platforms. ATGC also strives to serve the biomedical community with with our proprietary platforms and unique transgenic animal models. We encourage you to Contact us with your comments and questions so that we can better serve you.

SERVICES

Our mission is to discover the best-in-class therapeutics through the novel platforms. ATGC also strives to serve the biomedical community with products and technologies using our unique platforms.

Monoclonal antibody development

Stable expression cell line generation

Peptide synthesis and protein conjugation

Retrovirus and Lentivirus production

Mouse and Rabbit antibody humanization

Knock-out and Knock-in rabbit generation

PRODUCTS

TECHNOLOGIES

01

High knock-in rate gene editing enzyme miCas9

miCas9 is a fusion protein of the wild type Streptococcus pyogenes Cas9 (spCas9) with a 36 amino acid long fragment coded by BRCA2 …
02

SBEAD monoclonal antibody development platform

SBEAD is a cross species (rabbit, mouse, alpaca and more) platform for monoclonal antibody development. When used in rabbits, our special…
03

Gene knock-out and knock-in rabbits

ATGC founders are the pioneers in adopting the cutting-edge genome editing techniques for developing transgenic rabbits. Our expert …
Read moreRead more